We are developing cobitolimod to help patients with ulcerative colitis live a more normal life

Ulcerative colitis (UC) is a serious and chronic inflammatory bowel disease that currently has no cure. Approximately 0.2 percent of the world’s population suffers from UC and the number of persons living with the disease (the prevalence) is expected to increase by 0.8 percent every year. The risk of getting inflammatory bowel diseases has increased by more than ten times over the past 75 years.

In this section you will find out more about ulcerative colitis and today’s standard of care, as well as information about InDex’s leading drug candidate cobitolimod, a first in class treatment for moderate to severe ulcerative colitis.

Please use the left hand menu to find out more.